ATE319091T1 - Diagnose von einheimischer sprue/zöliakie mit hilfe von gliadinepitopen - Google Patents

Diagnose von einheimischer sprue/zöliakie mit hilfe von gliadinepitopen

Info

Publication number
ATE319091T1
ATE319091T1 AT00964460T AT00964460T ATE319091T1 AT E319091 T1 ATE319091 T1 AT E319091T1 AT 00964460 T AT00964460 T AT 00964460T AT 00964460 T AT00964460 T AT 00964460T AT E319091 T1 ATE319091 T1 AT E319091T1
Authority
AT
Austria
Prior art keywords
epitope
seq
coeliac disease
gliadin
sequence
Prior art date
Application number
AT00964460T
Other languages
English (en)
Inventor
Robert Paul Anderson
Adrian Vivian Sinton Hill
Derek Parry Jewell
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE319091T1 publication Critical patent/ATE319091T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
AT00964460T 1999-10-01 2000-10-02 Diagnose von einheimischer sprue/zöliakie mit hilfe von gliadinepitopen ATE319091T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923306.6A GB9923306D0 (en) 1999-10-01 1999-10-01 Diagnostic and therapeutic epitope, and transgenic plant

Publications (1)

Publication Number Publication Date
ATE319091T1 true ATE319091T1 (de) 2006-03-15

Family

ID=10861989

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00964460T ATE319091T1 (de) 1999-10-01 2000-10-02 Diagnose von einheimischer sprue/zöliakie mit hilfe von gliadinepitopen
AT05027922T ATE449965T1 (de) 1999-10-01 2000-10-02 Diagnostisches und therapeutisches epitop

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05027922T ATE449965T1 (de) 1999-10-01 2000-10-02 Diagnostisches und therapeutisches epitop

Country Status (15)

Country Link
US (5) US7144569B1 (de)
EP (2) EP1218751B1 (de)
JP (4) JP4932112B2 (de)
AT (2) ATE319091T1 (de)
AU (1) AU782262B2 (de)
CA (1) CA2386089C (de)
CY (2) CY1105282T1 (de)
DE (2) DE60043402D1 (de)
DK (2) DK1672368T3 (de)
ES (2) ES2256042T3 (de)
GB (1) GB9923306D0 (de)
HK (1) HK1088068A1 (de)
MX (1) MXPA02003295A (de)
PT (2) PT1672368E (de)
WO (1) WO2001025793A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923306D0 (en) * 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
ES2361993T5 (es) * 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
US7320788B2 (en) 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
AU2003234597A1 (en) * 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
EP1563300B1 (de) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnoseverfahren für sprue/zöliakie
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US20070185021A1 (en) * 2004-01-09 2007-08-09 Scott Fraser W Diabetogenic epitopes
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
CA2564521C (en) * 2004-04-28 2017-04-11 Btg International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
EP1612558A1 (de) * 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Verfahren zum Nachweis von Gluten
EP1993593B1 (de) * 2006-03-15 2015-08-26 Isocell S.A. Sod und peptidfragmente auf gliadinbasis enthaltende pharmazeutische zusammensetzungen
US7576040B2 (en) * 2007-01-11 2009-08-18 Halliburton Energy Services, Inc. Cement compositions comprising humic acid grafted fluid loss control additives
BRPI0808987A2 (pt) 2007-03-16 2014-09-09 Univ Leland Stanford Junior Terapia combinatória de enzima para digestão de glúten dietético
CN101821375B (zh) 2007-08-13 2013-07-10 联邦科学技术研究组织 具有低水平大麦醇溶蛋白的大麦
DK2977053T3 (en) 2008-11-30 2017-10-09 Immusant Inc COMPOSITIONS AND PROCEDURES FOR TREATMENT OF CELLIA
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
WO2012100070A2 (en) * 2011-01-20 2012-07-26 Immunosciences Lab, Inc. Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease
JP2014508517A (ja) * 2011-02-08 2014-04-10 ファディア・アクチボラゲット 小麦誘発過敏症診断用の小麦抗原およびペプチド
WO2012162697A1 (en) * 2011-05-26 2012-11-29 The Regents Of The University Of Colorado, A Body Corporate Compounds that modulate autoimmunity and methods of using the same
WO2014179202A1 (en) * 2013-05-02 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of celiac disease
EP2994480A4 (de) * 2013-05-08 2017-05-17 JM Biologicals Zusammensetzungen und verfahren zur herstellung glutenfreier nahrungsmittel
AU2014272810B2 (en) * 2013-05-14 2017-09-14 Oslo Universitetssykehus Hf Detection of gluten-specific T-cells
US10449228B2 (en) 2013-09-10 2019-10-22 Immusant, Inc. Dosage of a gluten peptide composition
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6744227B2 (ja) 2014-02-21 2020-08-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 糖標的化治療剤
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2015164717A1 (en) * 2014-04-24 2015-10-29 Immusant, Inc. Methods of diagnosis and treatment of celiac disease in children
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
EP3221344A2 (de) 2014-11-21 2017-09-27 Immusant Inc. Peptide zur behandlung und diagnose von typ-1-diabetes
EP3247384B1 (de) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro verfahren zur diagnose von typ-1-diabetes mit insulinmimotopen
DE102015204012A1 (de) 2015-03-05 2016-09-08 Clariant International Ltd. SCR-Katalysator mit verbesserter Haftung
EP3432877B1 (de) 2016-03-24 2023-01-11 ImmunoMolecular Therapeutics, Inc. D-alpha-methyldopa zur behandlung von autoimmunerkrankungen
US20200002709A1 (en) * 2016-09-01 2020-01-02 Cellectis Methods for altering amino acid content in plants
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN110128549B (zh) * 2019-05-27 2021-07-06 深圳市亚辉龙生物科技股份有限公司 脱酰胺基麦胶蛋白多肽重组抗原、重组抗原表达基因、重组表达载体及其制备方法和应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459355A (en) 1982-07-12 1984-07-10 International Paper Company Method for transforming plant cells
US4536475A (en) 1982-10-05 1985-08-20 Phytogen Plant vector
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
JPS6047683A (ja) * 1983-08-24 1985-03-15 Kirin Brewery Co Ltd プロモ−タ−
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4943674A (en) * 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
DK162399C (da) 1986-01-28 1992-03-23 Danisco Fremgangsmaade til ekspression af gener i baelgplanteceller, dna-fragment, rekombineret dna-fragment samt plasmid til brug ved udoevelsen af fremgangsmaaden
EP0242236B2 (de) 1986-03-11 1996-08-21 Plant Genetic Systems N.V. Durch Gentechnologie erhaltene und gegen Glutaminsynthetase-Inhibitoren resistente Pflanzenzellen
US5107065A (en) * 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5187073A (en) 1986-06-30 1993-02-16 The University Of Toledo Process for transforming gramineae and the products thereof
US5177010A (en) 1986-06-30 1993-01-05 University Of Toledo Process for transforming corn and the products thereof
NZ221259A (en) 1986-07-31 1990-05-28 Calgene Inc Seed specific transcriptional regulation
EP0267159A3 (de) 1986-11-07 1990-05-02 Ciba-Geigy Ag Verfahren zur genetischen Modifikation monokotyler Pflanzen
US4866247A (en) 1986-12-11 1989-09-12 The Lincoln Electric Company Apparatus and method of short circuiting arc welding
US4971908A (en) 1987-05-26 1990-11-20 Monsanto Company Glyphosate-tolerant 5-enolpyruvyl-3-phosphoshikimate synthase
US5356799A (en) 1988-02-03 1994-10-18 Pioneer Hi-Bred International, Inc. Antisense gene systems of pollination control for hybrid seed production
US5371014A (en) 1988-02-12 1994-12-06 Daicel Chemical Industries, Ltd. Process for the production of optically active 2-hydroxy acid esters using microbes to reduce the 2-oxo precursor
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5250515A (en) 1988-04-11 1993-10-05 Monsanto Company Method for improving the efficacy of insect toxins
US5565346A (en) 1988-07-27 1996-10-15 Calgene, Inc. Transformation and regeneration system for legumes
US5428146A (en) * 1988-11-07 1995-06-27 Max-Planck-Gesellschaft Zur Forderung Wound-stimulated DNA-sequence from solanum tuberosum and its use
US5110732A (en) 1989-03-14 1992-05-05 The Rockefeller University Selective gene expression in plants
US5086169A (en) 1989-04-20 1992-02-04 The Research Foundation Of State University Of New York Isolated pollen-specific promoter of corn
US5629183A (en) * 1989-05-08 1997-05-13 The United States Of America As Represented By The Secretary Of Agriculture Plant transformation by gene transfer into pollen
US5097025A (en) 1989-08-01 1992-03-17 The Rockefeller University Plant promoters
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
DE69031711T2 (de) 1989-08-09 1998-04-09 Dekalb Genetics Corp Methoden und zusammensetzungen für die herstellung von stabil transformierten, fruchtbaren mais pflanzen und zellen dafür
CA2071879C (en) 1989-10-27 2007-05-15 Stephen F. Heinemann Glutamate receptor compositions and methods
US5589583A (en) * 1990-01-11 1996-12-31 Monsanto Company Plant promoter
WO1991010725A1 (en) 1990-01-22 1991-07-25 Dekalb Plant Genetics Fertile transgenic corn plants
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
EP0442174A1 (de) 1990-02-13 1991-08-21 Pioneer Hi-Bred International, Inc. Stabile Transformation von Pflanzenzellen
US5618988A (en) 1990-03-02 1997-04-08 Amoco Corporation Enhanced carotenoid accumulation in storage organs of genetically engineered plants
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5187267A (en) 1990-06-19 1993-02-16 Calgene, Inc. Plant proteins, promoters, coding sequences and use
EP0536330B1 (de) 1990-06-25 2002-02-27 Monsanto Technology LLC Glyphosattolerante pflanzen
NZ239977A (en) 1990-11-14 1993-08-26 Pioneer Hi Bred Int Transforming plants by the use of agrobacterium
US5932782A (en) 1990-11-14 1999-08-03 Pioneer Hi-Bred International, Inc. Plant transformation method using agrobacterium species adhered to microprojectiles
WO1992009587A1 (en) 1990-11-26 1992-06-11 E.I. Du Pont De Nemours And Company Herbicidal oxazine ethers
US5459252A (en) 1991-01-31 1995-10-17 North Carolina State University Root specific gene promoter
EP0570422B1 (de) 1991-02-07 2007-12-19 Bayer BioScience N.V. Staubblatt spezifische promotoren aus mais
IL101508A0 (en) 1991-04-08 1992-12-30 Rhone Poulenc Agrochimie Chimeric plant genes based on upstream regulatory elements of helianthinin
DE69232132T3 (de) 1991-05-15 2008-08-14 Monsanto Technology Llc. Verfahren zur schöpfung einer transformierten reispflanze
AU2515592A (en) 1991-08-23 1993-03-16 University Of Florida A novel method for the production of transgenic plants
DE69334225D1 (de) 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
JP3633616B2 (ja) 1992-10-29 2005-03-30 トポターゲット ユーケー リミテッド 転写因子ｄｐ−１
US5389226A (en) 1992-12-17 1995-02-14 Amorphous Technologies International, Inc. Electrodeposition of nickel-tungsten amorphous and microcrystalline coatings
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
WO1994025613A1 (en) * 1993-05-03 1994-11-10 Cornell Research Foundation, Inc. Isolated dna elements that direct pistil-specific and anther-specific gene expression and methods of using same
US5670349A (en) 1993-08-02 1997-09-23 Virginia Tech Intellectual Properties, Inc. HMG2 promoter expression system and post-harvest production of gene products in plants and plant cell cultures
AU687863B2 (en) 1993-09-03 1998-03-05 Japan Tobacco Inc. Method of transforming monocotyledon by using scutellum of immature embryo
WO1995019030A1 (en) * 1994-01-05 1995-07-13 Pois, Inc. Apparatus and method for a personal onboard information system
US5495007A (en) 1994-04-29 1996-02-27 Thompson; Gary A. Phloem-specific promoter
US5459007A (en) * 1994-05-26 1995-10-17 Xerox Corporation Liquid developer compositions with block copolymers
US5633363A (en) 1994-06-03 1997-05-27 Iowa State University, Research Foundation In Root preferential promoter
US5646333A (en) 1994-09-02 1997-07-08 Drexel University Plant promoter useful for directing the expression of foreign proteins to the plant epidermis
HUT76355A (en) 1995-11-24 1997-08-28 Bay Zoltan Alkalmazott Kutatas Plant gene-expression vector family based on dna fragments regulating alfalfa h3 histon gene variant (ms h3g1)
US6036983A (en) * 1996-05-20 2000-03-14 Novo Nordisk A/S Method of obtaining protein hydrolysates
CA2257972A1 (en) 1996-06-13 1997-12-18 Consejo Superior De Investigaciones Cientificas Plant proteins
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
US5977436A (en) 1997-04-09 1999-11-02 Rhone Poulenc Agrochimie Oleosin 5' regulatory region for the modification of plant seed lipid composition
US5959175A (en) 1997-04-09 1999-09-28 Thomas; Terry L. Sunflower albumin 5' regulatory region for the modification of plant seed lipid composition
ES2132025B1 (es) 1997-06-12 2000-12-01 Consejo Superior Investigacion Proteinas urag de las plantas.
EP0905518A1 (de) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptiden spezifisch für Glutenempfindliche T-Zellen und Verwendung davon
US6100450A (en) 1997-10-22 2000-08-08 Rhone-Poulenc Agrochimie Seed specific promoters based on arabidopsis genes
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
WO1999053075A2 (en) 1998-04-09 1999-10-21 E.I. Du Pont De Nemours And Company Cell cycle regulatory proteins cdc-16, dp-1, dp-2 and e2f from plants
EP1084249A2 (de) 1998-05-08 2001-03-21 Consejo Superior De Investigaciones Cientificas Transgene pflanzenzellen welche ein rekombinantes pflanzliches e2f peptid exprimieren
WO2000047614A1 (en) 1999-02-12 2000-08-17 Pioneer Hi-Bred International, Inc. Transgenic plants with modified expression of the dp protein
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
EP1377604B1 (de) 2001-04-12 2014-12-31 Academisch Ziekenhuis Leiden Methoden und mittel zur verwendung von auf hla-dq beschränkten t-zell rezeptorensowie hla-dq-bindenden, von prolamin abstammenden, peptiden
DE60221700T2 (de) * 2001-12-11 2008-04-30 Tagsys S.A. Systeme zum sicheren markieren von daten
EP1332760A1 (de) 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Neue Epitope für Zöliakie und Autoimmunerkrankungen, Methoden zu deren Detektion und neue nichtantigene Futterzusätze
ES2361993T5 (es) * 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
EP1563300B1 (de) * 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnoseverfahren für sprue/zöliakie
US7144567B2 (en) * 2002-12-16 2006-12-05 Erling Jim Andersen Renewable energy carrier system and method

Also Published As

Publication number Publication date
WO2001025793A2 (en) 2001-04-12
JP2003511670A (ja) 2003-03-25
US7144569B1 (en) 2006-12-05
DE60026332D1 (de) 2006-04-27
CA2386089C (en) 2016-06-21
JP2016164169A (ja) 2016-09-08
EP1672368B1 (de) 2009-11-25
US20110044912A2 (en) 2011-02-24
EP1672368A1 (de) 2006-06-21
MXPA02003295A (es) 2002-09-02
US20090269285A1 (en) 2009-10-29
US20130318648A1 (en) 2013-11-28
JP6139154B2 (ja) 2017-05-31
AU7539400A (en) 2001-05-10
JP2013126991A (ja) 2013-06-27
HK1088068A1 (en) 2006-10-27
CY1105282T1 (el) 2010-03-03
US7888460B2 (en) 2011-02-15
EP1218751A2 (de) 2002-07-03
DE60043402D1 (de) 2010-01-07
JP2010263898A (ja) 2010-11-25
PT1218751E (pt) 2006-06-30
DK1672368T3 (da) 2010-01-04
ES2256042T3 (es) 2006-07-16
CA2386089A1 (en) 2001-04-12
DE60026332T2 (de) 2006-08-10
CY1109837T1 (el) 2014-09-10
US20080175971A1 (en) 2008-07-24
JP5371890B2 (ja) 2013-12-18
DK1218751T3 (da) 2006-07-03
ES2335895T3 (es) 2010-04-06
US20180057547A1 (en) 2018-03-01
PT1672368E (pt) 2010-01-20
US8329144B2 (en) 2012-12-11
ATE449965T1 (de) 2009-12-15
EP1218751B1 (de) 2006-03-01
AU782262B2 (en) 2005-07-14
WO2001025793A3 (en) 2001-08-23
GB9923306D0 (en) 1999-12-08
JP4932112B2 (ja) 2012-05-16

Similar Documents

Publication Publication Date Title
ATE319091T1 (de) Diagnose von einheimischer sprue/zöliakie mit hilfe von gliadinepitopen
NO975435L (no) Modifiserte/kimeriske proteiner samt anvendelse derav
EP0175360A3 (de) Antikörper gegen Petide und ihre Verwendung zum Nachweis von Onkogene-Produkten
YU193887A (en) PROCESS FOR OBTAINING APOLYPOPROTEINE "Al"
ES2133269T3 (es) Gen receptor del factor de crecimiento derivado de plaquetas de tipo oc.
Chiou A novel crystallin from octopus lens
DE60138703D1 (de) Transportpeptide abgeleitet von erns protein
EP0177814A3 (de) Antikörper gegen Peptide und ihre Verwendung zum Nachweis von Onkogene-Produkten
KR970706306A (ko) 펩티드들과 그들을 포함하는 약학적 조성물들
NZ233328A (en) Polypeptides produced by hepatocytes infected with p. falciparum; nucleic acid probes
NO178504C (no) Fr.måte for fr.stilling av minaktivin,DNA-molekyl,gen,vert,prober,preparat som omfatter prober,reagens for lokalisering og defini. av grenser for tumor i histologiske pröver,samt anvendelse av DNA-molekyl,minaktivin og preparat
DE69017352D1 (de) An HIV relatierte Peptide.
WO1995021916A3 (en) Pp32: a newly identified cd45-associated protein
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
Sanger Les Prix Nobel en 1958
Khalikov et al. Synthesis of new fragments of VP1 protein fragments from foot and mouth disease virus type A22. Synthesis of fragments 134-139, 134-145, 140-145, 150-155, and 150-159
Sanger Les Prix Nobel en
DK418587A (da) Fremgangsmaade til analyse af immunogene peptidsekvenser
WO2002024913A3 (en) 32612, a novel human peptide transporter and uses therefor
TH54460A3 (th) สารผสมฟลินท์ (flint) และการใช้ของสารผสม
TH43074A (th) โปรตีนเชื่อมกลูโคสดีไฮโดรจีเนส และการใช้ของมันในระบบการแสดงลักษณะ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1218751

Country of ref document: EP